• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Catalent, Rutgers partner to study pediatric drug formulation and delivery

July 20, 2017 By Sarah Faulkner

Catalent

The Catalent Applied Drug Delivery Institute said today that it inked a deal to work with the dept. of pharmacy practice at Rutgers University in an effort to identify and address the challenges linked to pediatric drug formulation and delivery.

The collaboration plans to focus on the development and administration of medicines to children by identifying conditions that have a high need for kid-friendly formulations.

“Clinical experience has shown us that current pediatric drug formulations are often difficult to administer to children and increase the likelihood for a medication error when compared with adult formulations. There is a clear need for research in this area, to further elucidate the gaps in drug delivery for young children, and in order to improve therapeutic outcomes and the patient experience,” Rachel Meyers, from the Ernest Mario School of Pharmacy at Rutgers University, said in prepared remarks.

“Through this exciting partnership, we will examine and highlight the unmet scientific, clinical, and patient needs, and look to develop a suitable pediatric-specific drug formulation toolkit to address them,” Cornell Stamoran, founder of the Catalent Applied Drug Delivery Institute and Catalent’s VP of strategy, added. “Most initiatives focus on individual new drugs or disease areas – we’re collaborating to identify a broad platform, founded on rigorous stakeholder insights, to establish a foundation for future pediatric drug development.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Pediatrics, Research & Development Tagged With: Catalent, rutgersuniversity

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS